Literature DB >> 16287098

Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).

Shunji Tomatsu1, Adriana M Montaño, Tatsuo Nishioka, Monica A Gutierrez, Olga M Peña, Georgeta G Tranda Firescu, Patricia Lopez, Seiji Yamaguchi, Akihiko Noguchi, Tadao Orii.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA; Morquio A disease) is an autosomal-recessive disorder caused by a deficiency of lysosomal N-acetylgalactosamine-6-sulfate sulfatase (GALNS; E.C.3.1.6.4). GALNS is required to degrade glycosaminoglycans, keratan sulfate (KS), and chondroitin-6-sulfate. Accumulation of undegraded substrates in lysosomes of the affected tissues leads to a systemic bone dysplasia. We summarize information on 148 unique mutations determined to date in the GALNS gene, including 26 novel mutations (19 missense, four small deletions, one splice-site, and two insertions). This heterogeneity in GALNS gene mutations accounts for an extensive clinical variability within MPS IVA. Seven polymorphisms that cause an amino acid change, and nine silent variants in the coding region are also described. Of the analyzed mutant alleles, missense mutations accounted for 78.4%; small deletions, 9.2%; nonsense mutation, 5.0%; large deletion, 2.4%; and insertions, 1.6%. Transitional mutations at CpG dinucleotides accounted for 26.4% of all the described mutations. The importance of the relationship between methylation status and distribution of transitional mutations at CpG sites at the GALNS gene locus was elucidated. The three most frequent mutations (over 5% of all mutations) were represented by missense mutations (p.R386C, p.G301C, and p.I113F). A genotype/phenotype correlation was defined in some mutations. Missense mutations associated with a certain phenotype were studied for their effects on enzyme activity and stability, the levels of blood and urine KS, the location of mutations with regard to the tertiary structure, and the loci of the altered amino acid residues among sulfatase proteins. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16287098     DOI: 10.1002/humu.20257

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  54 in total

1.  Spondyloepiphyseal dysplasias and bilateral legg-calvé-perthes disease: diagnostic considerations for mucopolysaccharidoses.

Authors:  Nancy J Mendelsohn; Timothy Wood; Rebecca A Olson; Renee Temme; Susan Hale; Haoyue Zhang; Lisa Read; Klane K White
Journal:  JIMD Rep       Date:  2013-05-09

Review 2.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

3.  Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre's experience.

Authors:  A Broomfield; K Zuberi; J Mercer; G Moss; N Finnegan; P Hensman; R Walker; S Bukhari; N B Wright; F Stewart; S A Jones; R Ramirez
Journal:  Childs Nerv Syst       Date:  2018-06-26       Impact factor: 1.475

4.  Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations.

Authors:  Laura M Pollard; Julie R Jones; Tim C Wood
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

5.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

6.  Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21.

Authors:  Alexander Rodríguez; Angela J Espejo; Alejandra Hernández; Olga L Velásquez; Lina M Lizaraso; Henry A Cordoba; Oscar F Sánchez; Carlos J Alméciga-Díaz; Luis A Barrera
Journal:  J Ind Microbiol Biotechnol       Date:  2010-06-27       Impact factor: 3.346

7.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

8.  Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  Carlos J Alméciga-Díaz; Maria A Rueda-Paramo; Angela J Espejo; Olga Y Echeverri; Adriana Montaño; Shunji Tomatsu; Luis A Barrera
Journal:  Mol Biol Rep       Date:  2008-11-07       Impact factor: 2.316

9.  Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.

Authors:  Vũ Chí Dũng; Shunji Tomatsu; Adriana M Montaño; Gary Gottesman; Michael B Bober; William Mackenzie; Miho Maeda; Grant A Mitchell; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-26       Impact factor: 4.797

10.  Bromocriptine as a Novel Pharmacological Chaperone for Mucopolysaccharidosis IV A.

Authors:  Sergio Olarte-Avellaneda; Jacobo Cepeda Del Castillo; Andrés Felipe Rojas-Rodriguez; Oscar Sánchez; Alexander Rodríguez-López; Diego A Suárez García; Luz Mary Salazar Pulido; Carlos J Alméciga-Díaz
Journal:  ACS Med Chem Lett       Date:  2020-06-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.